{"id":"https://openalex.org/W2905375175","doi":"https://doi.org/10.1182/blood-2018-99-117521","title":"The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study","display_name":"The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2905375175","doi":"https://doi.org/10.1182/blood-2018-99-117521","mag":"2905375175"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-117521","doi":"https://doi.org/10.1182/blood-2018-99-117521","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-117521","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063755644","display_name":"Matthew Steven Davids","orcid":"https://orcid.org/0000-0003-4529-2003","observed_orcids":["https://orcid.org/0000-0003-4529-2003"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. Davids","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002467749","display_name":"Bryone Jean Kuss","orcid":"https://orcid.org/0000-0002-5811-1331","observed_orcids":["https://orcid.org/0000-0002-5811-1331"]},"institutions":[{"id":"https://openalex.org/I2802931750","display_name":"Flinders Medical Centre","ror":"https://ror.org/020aczd56","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2802931750"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Bryone J. Kuss","raw_affiliation_strings":["Department of Haematology, Flinders Medical Centre, Bedford Park, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Haematology, Flinders Medical Centre, Bedford Park, Australia","institution_ids":["https://openalex.org/I2802931750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047631289","display_name":"Peter Hillmen","orcid":"https://orcid.org/0000-0001-5617-4403","observed_orcids":["https://orcid.org/0000-0001-5617-4403"]},"institutions":[{"id":"https://openalex.org/I2801331674","display_name":"St James's University Hospital","ror":"https://ror.org/013s89d74","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799390153","https://openalex.org/I2801331674"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter Hillmen","raw_affiliation_strings":["St. James's University Hospital, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. James's University Hospital, Leeds, United Kingdom","institution_ids":["https://openalex.org/I2801331674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039819830","display_name":"Marco Montillo","orcid":"https://orcid.org/0000-0003-0010-032X","observed_orcids":["https://orcid.org/0000-0003-0010-032X"]},"institutions":[{"id":"https://openalex.org/I4210094195","display_name":"Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda","ror":"https://ror.org/00htrxv69","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210094195"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Marco Montillo","raw_affiliation_strings":["Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy","institution_ids":["https://openalex.org/I4210094195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044422916","display_name":"James H. Essell","orcid":"https://orcid.org/0000-0002-9173-0310","observed_orcids":["https://orcid.org/0000-0002-9173-0310"]},"institutions":[{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Essell","raw_affiliation_strings":["Oncology/Hematology Care, Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology/Hematology Care, Cincinnati, OH","institution_ids":["https://openalex.org/I4210153992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010100538","display_name":"Nicole Lamanna","orcid":"https://orcid.org/0000-0003-3331-9491","observed_orcids":["https://orcid.org/0000-0003-3331-9491"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nicole Lamanna","raw_affiliation_strings":["Hematology/Oncology Division, Columbia University Medical Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology Division, Columbia University Medical Center, New York, NY","institution_ids":["https://openalex.org/I2799503643"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101865823","display_name":"Zsolt Nagy","orcid":"https://orcid.org/0000-0001-9756-5427","observed_orcids":["https://orcid.org/0000-0001-9756-5427"]},"institutions":[{"id":"https://openalex.org/I101202996","display_name":"Semmelweis University","ror":"https://ror.org/01g9ty582","country_code":"HU","type":"education","lineage":["https://openalex.org/I101202996"]}],"countries":["HU"],"is_corresponding":true,"raw_author_name":"Zsolt Nagy","raw_affiliation_strings":["1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary","institution_ids":["https://openalex.org/I101202996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034517642","display_name":"Constantine Si Lun Tam","orcid":"https://orcid.org/0000-0002-9759-5017","observed_orcids":["https://orcid.org/0000-0002-9759-5017"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I2800555584","display_name":"Peter MacCallum Cancer Centre","ror":"https://ror.org/02a8bt934","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I2800555584"]},{"id":"https://openalex.org/I4210087110","display_name":"St Vincent's Hospital Melbourne","ror":"https://ror.org/001kjn539","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210087110","https://openalex.org/I4210098850"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Constantine S. Tam","raw_affiliation_strings":["St Vincent's Hospital and University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St Vincent's Hospital and University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia","institution_ids":["https://openalex.org/I165779595","https://openalex.org/I2800555584","https://openalex.org/I4210087110"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5019866348","display_name":"Stephan Stilgenbauer","orcid":"https://orcid.org/0000-0002-6830-9296","observed_orcids":["https://orcid.org/0000-0002-6830-9296"]},"institutions":[{"id":"https://openalex.org/I196349391","display_name":"Universit\u00e4t Ulm","ror":"https://ror.org/032000t02","country_code":"DE","type":"education","lineage":["https://openalex.org/I196349391"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Stephan Stilgenbauer","raw_affiliation_strings":["Department of Internal Medicine III, Ulm University, Ulm, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Internal Medicine III, Ulm University, Ulm, Germany","institution_ids":["https://openalex.org/I196349391"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087770514","display_name":"Paolo Ghia","orcid":"https://orcid.org/0000-0003-3750-7342","observed_orcids":["https://orcid.org/0000-0003-3750-7342"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paolo Ghia","raw_affiliation_strings":["Fondazione Centro San Raffaele, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fondazione Centro San Raffaele, Milano, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014405902","display_name":"Julio Delgado","orcid":"https://orcid.org/0000-0002-5157-4376","observed_orcids":["https://orcid.org/0000-0002-5157-4376"]},"institutions":[{"id":"https://openalex.org/I4210115097","display_name":"Hospital Cl\u00ednic de Barcelona","ror":"https://ror.org/02a2kzf50","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210115097"]},{"id":"https://openalex.org/I4210160192","display_name":"Consorci Institut D'Investigacions Biomediques August Pi I Sunyer","ror":"https://ror.org/054vayn55","country_code":"ES","type":"facility","lineage":["https://openalex.org/I4210115097","https://openalex.org/I4210160192","https://openalex.org/I4387153040","https://openalex.org/I4403928279"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Julio Delgado","raw_affiliation_strings":["Servicio de Hematolog\u00eda, Hospital Cl\u00ednic, IDIBAPS, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Servicio de Hematolog\u00eda, Hospital Cl\u00ednic, IDIBAPS, Barcelona, Spain","institution_ids":["https://openalex.org/I4210115097","https://openalex.org/I4210160192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110509628","display_name":"Ngocdiep T. Le","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154584","display_name":"Verastem (United States)","ror":"https://ror.org/0562yk913","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154584"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"NgocDiep Le","raw_affiliation_strings":["Verastem Oncology, Needham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Verastem Oncology, Needham, MA","institution_ids":["https://openalex.org/I4210154584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006302059","display_name":"Stephanie Lustgarten","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210154584","display_name":"Verastem (United States)","ror":"https://ror.org/0562yk913","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154584"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Stephanie Lustgarten","raw_affiliation_strings":["Verastem Oncology, Needham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Verastem Oncology, Needham, MA","institution_ids":["https://openalex.org/I4210154584"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074838425","display_name":"David T. Weaver","orcid":"https://orcid.org/0000-0001-8398-3919","observed_orcids":["https://orcid.org/0000-0001-8398-3919"]},"institutions":[{"id":"https://openalex.org/I4210154584","display_name":"Verastem (United States)","ror":"https://ror.org/0562yk913","country_code":"US","type":"company","lineage":["https://openalex.org/I4210154584"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David T. Weaver","raw_affiliation_strings":["Verastem Oncology, Needham, MA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Verastem Oncology, Needham, MA","institution_ids":["https://openalex.org/I4210154584"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5113865605","display_name":"Ulrich Jaeger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210092129","display_name":"Comprehensive Cancer Center Vienna","ror":"https://ror.org/00df3z122","country_code":"AT","type":"healthcare","lineage":["https://openalex.org/I2802328216","https://openalex.org/I4210092129"]},{"id":"https://openalex.org/I76134821","display_name":"Medical University of Vienna","ror":"https://ror.org/05n3x4p02","country_code":"AT","type":"education","lineage":["https://openalex.org/I76134821"]}],"countries":["AT"],"is_corresponding":false,"raw_author_name":"Ulrich Jaeger","raw_affiliation_strings":["Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Medical University of Vienna, Vienna, Austria"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine I, Division of Hematology and Hemostaseology, and Comprehensive Cancer Center, Medical University of Vienna, Medical University of Vienna, Vienna, Austria","institution_ids":["https://openalex.org/I4210092129","https://openalex.org/I76134821"]}]}],"institutions":[],"countries_distinct_count":8,"institutions_distinct_count":16,"corresponding_author_ids":["https://openalex.org/A5006302059","https://openalex.org/A5101865823","https://openalex.org/A5110509628"],"corresponding_institution_ids":["https://openalex.org/I101202996","https://openalex.org/I4210154584"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"3140","last_page":"3140"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/duvelisib","display_name":"duvelisib","score":0.996999979019165},{"id":"https://openalex.org/keywords/ofatumumab","display_name":"ofatumumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.878000020980835},{"id":"https://openalex.org/keywords/small-lymphocytic-lymphoma","display_name":"small lymphocytic lymphoma","score":0.9100000262260437},{"id":"https://openalex.org/keywords/pi3kdelta-inhibitor","display_name":"PI3K\u03b4 inhibitor","score":0.6809999942779541},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.6209999918937683},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8119999766349792},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.5770000219345093},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4869999885559082},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6520000100135803},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.3569999933242798}],"concepts":[{"id":"https://openalex.org/C2778714382","wikidata":"https://www.wikidata.org/wiki/Q410656","display_name":"Ofatumumab","level":4,"score":0.8525183200836182},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6738337874412537},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.5473407506942749},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4742766320705414},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.45257940888404846},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.42942166328430176},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.37668830156326294},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.2813672423362732},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.272386372089386},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.09046268463134766},{"id":"https://openalex.org/C159985019","wikidata":"https://www.wikidata.org/wiki/Q181790","display_name":"Composite material","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-117521","doi":"https://doi.org/10.1182/blood-2018-99-117521","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-117521","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2891876928","https://openalex.org/W3001171775","https://openalex.org/W2895287765","https://openalex.org/W2784823232","https://openalex.org/W2951349998","https://openalex.org/W2912098275","https://openalex.org/W2961546232","https://openalex.org/W2950306720","https://openalex.org/W2908746125","https://openalex.org/W2988180727"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Duvelisib":[2],"(DUV),":[3],"an":[4,71,540,748,761,775,790,801,824,840,854,892,908,920,959,971,985,999,1013,1028,1044,1057,1074,1087,1107,1122,1137,1153,1168,1183,1198,1213,1228,1243,1258,1273,1288,1303],"oral,":[5],"first-in-class":[6],"dual":[7],"inhibitor":[8],"of":[9,17,127,171,218,239,249,259,345,370,384,411,426,460,529,686,696,705,734,751,764,778,793,804,827,843,857,895,911,923,962,974,988,1002,1016,1031,1047,1060,1077,1090,1110,1125,1140,1156,1171,1186,1201,1216,1231,1246,1261,1276,1291,1306],"PI3K-\u03b4,-\u03b3,":[10],"is":[11,70],"being":[12,547],"developed":[13],"for":[14,101,166,281,317,616],"the":[15,25,90,94,102,130,182,196,201,219,260,299,313,318,409,424,437,543,650,723,730],"treatment":[16,525,563],"hematologic":[18,474],"malignancies,":[19],"including":[20,653],"relapsed/refractory":[21],"(RR)":[22],"CLL/SLL.":[23,741],"In":[24,423],"Phase":[26],"3":[27,125,244,254],"DUO":[28,87,131,183,267,651,724],"study":[29,76,132,150,198,711],"(NCT02004522)":[30],"DUV":[31,115,139,187,303,332,378,397,418,441,446,477,587,626,659,677,706,720,735],"monotherapy":[32,43,188,627,648,707,721,736],"demonstrated":[33],"a":[34,59,343,368,382,454,516,532,681,691],"significant":[35],"improvement":[36],"in":[37,65,361,408,638,666,708,737],"efficacy":[38],"compared":[39,341,380,401],"to":[40,92,185,273,279,302,342,381,402,457,524,539,562,594,599,604,609,684,694,716],"ofatumumab":[41],"(OFA)":[42],"(median":[44,450],"PFS":[45],"[mPFS]":[46],"13.3":[47],"vs":[48,54,419],"9.9":[49],"mo.,":[50],"p<0.0001;":[51],"ORR":[52,395,438],"74%":[53],"45%,":[55],"p":[56],"<0.0001)":[57],"with":[58,80,164,247,264,291,363,413,453,515,519,542,640,655,680,719,739],"manageable":[60,713],"safety":[61,703],"profile":[62,704],"(Flinn,":[63],"Blood,":[64],"press).":[66],"Study":[67,117,184,193,589],"IPI-145-12":[68,118],"(NCT02049515)":[69],"open-label,":[72],"optional,":[73],"crossover":[74,710],"extension":[75],"where":[77],"patients":[78],"(pts)":[79],"radiologically":[81],"confirmed":[82],"progressive":[83],"disease":[84],"(PD)":[85],"on":[86,110,116,129,181,192,266,323,327,331,352,377,391,396,404,417,421,433,440,445,476,588,623,649,673,676,722,747,760,774,789,800,823,839,853,891,907,919,958,970,984,998,1012,1027,1043,1056,1073,1086,1106,1121,1136,1152,1167,1182,1197,1212,1227,1242,1257,1272,1287,1302],"were":[88,153,210],"given":[89],"option":[91],"receive":[93,186,274],"opposite":[95],"treatment.":[96],"Here":[97],"we":[98],"present":[99],"data":[100,727],"90":[103,175,258,283],"pts":[104,122,176,220,250,262,284,362,412,427,512,530,583,621,639,654,667,738],"who":[105,268,366,429,643,668],"crossed":[106,177,271],"over":[107,178,272],"following":[108,646],"PD":[109,128,270,645],"OFA":[111,180,265,280,324,353,392,405,434,647],"(pre-crossover)":[112],"and":[113,212,229,325,407,481,504,507,555,578,613,630,690,714],"received":[114,252],"(post-crossover).":[119],"Methods:":[120],"Eligible":[121],"enrolled":[123],"within":[124],"months":[126,336,347,372,386,462,698],"(excluding":[133],"Richter's":[134],"transformation":[135],"or":[136,149,225,753,766,780,795,806,829,845,859,897,913,925,964,976,990,1004,1018,1033,1049,1062,1079,1092,1112,1127,1142,1158,1173,1188,1203,1218,1233,1248,1263,1278,1293,1308],"prolymphocytic":[137],"leukemia).":[138],"25":[140,189],"mg":[141,190],"BID":[142,191],"was":[143,204,243,285,304,334,357,399,415,442,678,712],"administered":[144],"until":[145],"PD,":[146,600],"intolerance,":[147],"death,":[148,605],"withdrawal.":[151],"Responses":[152],"determined":[154],"by":[155],"investigators":[156],"per":[157],"IWCLL":[158],"(Cheson":[159,162],"2011)/IWG":[160],"criteria":[161],"2007)":[163],"modification":[165,534],"treatment-related":[167],"lymphocytosis.":[168],"Results:":[169],"As":[170],"15":[172,335,636],"June":[173],"2018,":[174],"from":[179],"IPI-145-12.":[194],"At":[195],"initial":[197],"entry":[199],"(DUO)":[200],"median":[202,237,277,300,455,682,692],"age":[203],"68":[205],"yrs":[206],"(range:":[207,245,288,307],"39-89);":[208],"63%":[209],"male;":[211],"90%":[213],"Caucasian.":[214],"Nearly":[215],"half":[216],"(49%)":[217],"had":[221,231,269,367,430,513,531,644,669],"Rai":[222],"Stage":[223,227],"III/IV":[224],"Binet":[226],"C,":[228],"23%":[230],"del(17p)":[232,364,414,656],"and/or":[233,536],"TP53":[234],"mutation.":[235],"The":[236,276,329,394,467,484,702],"number":[238],"prior":[240,255,671],"anticancer":[241,256],"therapies":[242],"2-8),":[246],"60%":[248],"having":[251],"\u2265":[253],"therapies.":[257],"101":[261],"treated":[263],"DUV.":[275,328,624],"exposure":[278,301],"these":[282],"23":[286],"weeks":[287,306],"1-26":[289],"weeks),":[290],"61%":[292],"receiving":[293],"all":[294],"12":[295],"prescribed":[296],"infusions.":[297],"Post-crossover,":[298],"43":[305],"2-170":[308],"weeks).":[309],"Table":[310],"1":[311,520,688],"shows":[312],"overall":[314],"response":[315,432,459,465,672,695,700],"rate":[316],"same":[319],"pt":[320],"set":[321],"pre-crossover":[322,435],"post-crossover":[326,333,379,398,439],"mPFS":[330,344,369,383,635],"(95%":[337,348,373,387],"CI:":[338,349,374,388],"12,":[339],"20)":[340],"9":[346],"9,":[350,375],"11)":[351,390],"pre-crossover.":[354,393],"This":[355],"difference":[356],"even":[358],"more":[359],"pronounced":[360],"(n=20),":[365],"17":[371,619],"21)":[376],"8":[385],"5,":[389],"77%":[400],"29%":[403],"pre-crossover,":[406],"subset":[410,425],"80%":[416],"15%":[420],"OFA.":[422,674],"(n=47)":[428],"no":[431,670],"(SD/PD),":[436],"73%.":[443],"Pts":[444],"achieved":[447,628],"rapid":[448],"lymphocytosis":[449,685],"1.1":[451],"months)":[452,637],"time":[456,683,693],"first":[458,464],"2.6":[461],"(i.e.,":[463],"assessment).":[466,701],"most":[468,485,544],"common":[469,486,545],"severe":[470,487],"(\u2265":[471,565],"Gr":[472],"3)":[473],"AEs":[475,489,514,560],"included":[478,490,568],"neutropenia":[479,554],"(23%)":[480],"thrombocytopenia":[482],"(4%).":[483],"non-hematologic":[488],"diarrhea":[491,548,572],"(21%),":[492],"pneumonia":[493,550,575],"(12%),":[494],"colitis":[495,552,569],"(11%),":[496],"lipase":[497,556],"increased":[498,557],"(7%),":[499],"acute":[500],"renal":[501],"failure":[502],"(6%),":[503],"bronchitis,":[505],"rash,":[506],"sepsis":[508],"(4%,":[509],"each).":[510,559],"Nine":[511],"fatal":[517],"outcome":[518],"assessed":[521],"as":[522],"related":[523],"(PJP).":[526],"Approximately":[527],"70%":[528],"dose":[533],"(interruption":[535],"reduction)":[537],"due":[538,593,598,603,608],"AE,":[541],"(>5%)":[546],"(27%),":[549],"(10%),":[551],"(8%),":[553],"(7%":[558],"leading":[561],"discontinuation":[564],"2":[566],"pts)":[567],"(n=9;":[570],"10%),":[571],"(n=8;":[573],"9%),":[574],"(n=2;":[576,580],"2%),":[577],"rash":[579],"2%).":[581],"Seventy-three":[582],"(81%)":[584],"have":[585],"discontinued":[586],"IPI-145-12,":[590],"39":[591],"(43%)":[592],"AEs,":[595],"19":[596],"(21%)":[597],"6":[601],"(7%)":[602],"5":[606],"(6%)":[607],"voluntary":[610],"withdrawal/investigator":[611],"decision,":[612],"4":[614],"(4%)":[615],"other":[617],"reasons;":[618],"(19%)":[620],"remain":[622],"Conclusions:":[625],"robust":[629],"durable":[631],"responses":[632],"(ORR":[633,657,664],"77%,":[634],"RR":[641,740],"CLL/SLL":[642],"study,":[652],"80%).":[658],"also":[660],"showed":[661],"strong":[662],"activity":[663],"73%)":[665],"Response":[675],"rapid,":[679],"~":[687],"month":[689],"~2":[697],"(first":[699],"this":[709],"similar":[715],"that":[717],"observed":[718],"study.":[725],"These":[726],"further":[728],"support":[729],"potential":[731],"clinical":[732],"benefit":[733],"Disclosures":[742],"Davids:":[743],"Janssen:":[744,887,948,1097,1238,1338],"Consultancy,":[745,758,772,787,811,821,837,851,870,888,934,939,944,949,956,968,982,996,1010,1025,1040,1053,1070,1083,1098,1103,1118,1133,1149,1164,1179,1194,1209,1224,1239,1254,1269,1284,1299],"Membership":[746,759,773,788,799,822,838,852,890,906,918,957,969,983,997,1011,1026,1042,1055,1072,1085,1105,1120,1135,1151,1166,1181,1196,1211,1226,1241,1256,1271,1286,1301],"entity's":[749,762,776,791,802,825,841,855,893,909,921,960,972,986,1000,1014,1029,1045,1058,1075,1088,1108,1123,1138,1154,1169,1184,1199,1214,1229,1244,1259,1274,1289,1304],"Board":[750,763,777,792,803,826,842,856,894,910,922,961,973,987,1001,1015,1030,1046,1059,1076,1089,1109,1124,1139,1155,1170,1185,1200,1215,1230,1245,1260,1275,1290,1305],"Directors":[752,765,779,794,805,828,844,858,896,912,924,963,975,989,1003,1017,1032,1048,1061,1078,1091,1111,1126,1141,1157,1172,1187,1202,1217,1232,1247,1262,1277,1292,1307],"advisory":[754,767,781,796,807,830,846,860,898,914,926,965,977,991,1005,1019,1034,1050,1063,1080,1093,1113,1128,1143,1159,1174,1189,1204,1219,1234,1249,1264,1279,1294,1309],"committees;":[755,797,808,915,966,1020,1035,1051,1081],"TG":[756],"Therapeutics:":[757,952],"committees,":[768,782,831,847,861,899,927,978,992,1006,1064,1094,1114,1129,1144,1160,1175,1190,1205,1220,1235,1250,1265,1280,1295,1310],"Research":[769,783,812,816,832,848,862,865,873,879,885,900,903,928,931,936,953,979,993,1007,1022,1037,1065,1095,1100,1115,1130,1145,1161,1176,1191,1206,1221,1236,1251,1266,1281,1296,1311,1315,1319,1323,1327,1332,1336,1340],"Funding;":[770,784,813,817,833,849,863,874,880,886,901,904,929,937,954,980,994,1008,1023,1096,1116,1131,1146,1162,1177,1192,1207,1222,1237,1252,1267,1282,1297,1316,1320,1324,1328,1333,1337],"Pharmacyclics:":[771,872,955,1069],"AbbVie,":[785,1329],"Inc:":[786,869,1330],"Gilead:":[798,938,981,1132,1334],"MEI":[809],"Pharma:":[810],"Surface":[814],"Oncology:":[815,1343,1346],"Merck:":[818],"Consultancy;":[819,835],"Astra-Zeneca:":[820],"Celgene:":[834,930,1024,1253],"Verastem:":[836,1036],"Roche/Genentech:":[850],"BMS:":[864],"Funding.":[866,932,1038,1101,1312,1341],"Hillmen:Alexion":[867],"Pharmaceuticals,":[868],"Honoraria;":[871],"F.":[875],"Hoffmann-La":[876],"Roche":[877],"Ltd:":[878],"Gilead":[881],"Sciences,":[882],"Inc.:":[883],"Honoraria,":[884,889,917,935,940,945,1041,1054,1071,1084,1099,1104,1119,1134,1150,1165,1180,1195,1210,1225,1240,1255,1270,1285,1300,1314,1318,1322,1326,1331,1335,1339],"Novartis:":[902,1268,1325],"Acerta:":[905,1021],"Abbvie:":[916,967,1052],"Montillo:Roche:":[933],"Speakers":[941,946,1067],"Bureau;":[942,947,1068],"AbbVie:":[943,1298],"Honoraria.":[950],"Lamanna:TG":[951],"AstraZeneca:":[995],"Jannsen:":[1009],"Tam:Gilead:":[1039],"Funding,":[1066],"BeiGene:":[1082,1317],"Stilgenbauer:Mundipharma:":[1102],"Sanofi:":[1117],"Hoffmann":[1147],"La-Roche:":[1148],"Pharmcyclics:":[1163],"Genentech:":[1178],"Amgen:":[1193],"Boehringer-Ingelheim:":[1208],"Genzyme:":[1223],"GSK:":[1283],"Ghia:Acerta:":[1313],"Sunesis:":[1321],"Le:Verastem":[1342],"Employment.":[1344,1347],"Lustgarten:Verastem":[1345],"Weaver:":[1348]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-12-22T00:00:00"}